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Introduction: Gastrointestinal stromal tumors are rare tumors. They commonly metastasize within the abdominal
cavity, particularly to the liver. Less commonly, metastases can be found in the bone.
Case presentation: We here present a case of metastasis to the scapula in a 54-year-old Caucasian male patient
with an advanced gastrointestinal stromal tumor, which was subsequently successfully treated with resection and
sunitinib.
Conclusion: The present study is, to the best of our knowledge, the second to describe scapular metastasis of a
gastrointestinal stromal tumor. Our patient was treated by scapulectomy. The overwhelming majority of scapular
tumors are metastases that arise from soft tissue, hepatocellular and thyroid tumors. Gastrointestinal stromal tumor
metastasis occurs rarely. Scapular surgery can successfully provide local control of the disease. After the surgery,
patients should continue with medical treatment.Introduction
Gastrointestinal stromal tumors (GISTs) are the most
common connective tissue tumors of the gastrointestinal
(GI) tract [1]. GISTs originate from the interstitial cells
of Cajal [2]. These cells are a type of interstitial cell
found in the GI tract and are involved in the generation
of electrical pacemaker activity for GI motility. The ma-
jority of GISTs are associated with activating mutations
in the KIT gene or platelet-derived growth factor recep-
tor alpha (PDGFRα) [3]. Ten to twenty patients in every
one million have a new diagnosis of GIST per year in
the US and 5,000 to 6,000 cases are diagnosed every
year. In Europe, the incidence is estimated to be 6.6 to
14.5 cases in every 3 million to 7 million people [4,5].
Surgery is the standard treatment for primary resect-
able GISTs; however, surgical resection is seldom cura-
tive and by five years after complete removal, 40% of
patients have relapsed [6]. Imatinib is the first-line treat-
ment in patients with metastatic or unresectable GISTs.
Its use results in durable objective response or stable
disease in approximately 85% of patients with advanced* Correspondence: deniztural@gmail.com
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distribution, and reproduction in any mediumGISTs, and it is well tolerated [7,8]. Sunitinib is the
recommended option for documented GISTs (resectable,
unresectable, recurrent or metastatic disease) in patients
that experience life-threatening side effects from imati-
nib therapy, and as a treatment for unresectable or
metastatic disease following unsuccessful imatinib treat-
ment [9].Case presentation
A 54-year-old Caucasian male patient with no previous his-
tory of any disease was referred to our clinic on January
2001 with rectal bleeding. A colonoscopy showed an ulcer-
ated polypoid mass in his rectum that was 12 cm distant
from the anal verge. A pathological examination of the bi-
opsied specimens revealed a GIST. Surgery was performed
and the mass was excised by en bloc resection technique. A
computed tomography (CT) scan of his thorax demon-
strated no pathological finding. Multiple and non-
resectable bilobar liver metastases were found on abdom-
inal magnetic resonance imaging (MRI). Our patient was
started on imatinib 400 mg daily in 2001. After an event-
free follow-up period, our patient was readmitted in 2010
with complaints of right shoulder pain and limitation of
shoulder movement. His liver metastases were seen to bentral Ltd This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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rence was found during a colonoscopic examination.
MRI showed a 13 cm×10 cm×7 cm mass with partial
contrast-enhancement that was T1- and T2-hyperintense
and heterogeneous. The mass was destroying the body of
his right scapula and had widespread involvement in the
infraspinatus muscle. A fluorodeoxyglucose positron
emission tomography (PET)-CT showed a hypermeta-
bolic mass in his posterior right shoulder (Figure 1). The
mass was resected (Figure 2). On microscopy, the tumor
was composed of an interlacing pattern of spindle cells
that stained negative for smooth muscle actin, and posi-
tive for CD117 (c-kit) and CD34 (Figure 3). Pathologic
findings were compatible with metastasis of GIST to the
scapula. Following resection, his imatinib therapy was
changed to sunitinib. At the time this report was written,
our patient was still taking sunitinib 50 mg daily.Discussion
GISTs are mesenchymal tumors with generic histological
features that arise from the gastrointestinal or abdominal
tract. GISTs originate from interstitial cells of Cajal - intes-
tinal pacemaker cells that arise from the muscularis pro-
pria of the gastrointestinal tract wall [10]. The c-kit gene
encodes an oncogenic transmembrane receptor tyrosine
kinase (KIT), whose ligand is a stem cell factor. TheFigure 1 Fluorodeoxyglucose positron emission tomography-comput
(12.3 mCi) of F-18 fluorodeoxyglucose after 6 hours of fasting. After one ho
integrated positron emission tomography-computed tomography camera,
on a lutetium oxyorthosilicate-based fullring positron emission tomography
maximum intensity projection positron emission tomography image; (B) ax
intense hypermetabolic mass with a maximum standard uptake value (SUV
shoulder. (C) Axial computed tomography image shows a soft tissue mass
intensity projection image shows another focus of fluorodeoxyglucose uptPDGFRα gene also encodes an oncogenic transmembrane
receptor tyrosine kinase (PDGFRα).
Gain of function mutations of the c-kit and PDGFRα
genes are associated with the tumorigenesis of GISTs.
The most frequent mutations are observed in the juxta-
membrane domain of KIT, which is coded by exon 11.
Mutations in the extracellular domain of KIT exon 9 are
seen less often. Although most GISTs express KIT (95%),
a minority will be negative for KIT or express wild-type
KIT [11]; however, in some GISTs, a mutation cannot be
detected. The epidemiology of GISTs is not fully known;
on average, 10 cases per million individuals are thought
to occur. Most patients are aged 40 to 80 years old and
are diagnosed at a median age of 60 years [12].
GISTs commonly occur in the stomach (50% to 60%)
and small intestine (25%). They can also occur in the col-
orectum (10%), esophagus (5%), anywhere along the GI
tract and, rarely, in extraintestinal sites, including the
mesentery, omentum, peritoneum, gallbladder and liver
(3%) [13]. The clinical presentation of GISTs is largely
dependent on size. Small tumors (≤2 cm) usually do not
produce symptoms and are often detected incidentally
via endoscopy or radiographic examination. Several
major symptoms, which are not only GIST-related,
include bleeding, upper abdominal pain, fullness and
abdominal mass and obstruction [14]. Sometimes, urgent
abdominal complaints, such as abdominal bleeding,ed tomography. The patient was intravenously injected 455 MBq
ur of waiting time in a silent room, the patient was imaged using an
which consists of a six-slice computed tomography gantry integrated
scanner (Siemens Biograph 6, IL, USA). (A) Anterior-posterior
ial positron emission tomography and (D) axial fusion images show
max) of 15.2 at the level of infraspinatus muscle in the right posterior
destructing the right scapula in the right posterior shoulder. Maximum
ake in the midline of the upper pelvis.
Figure 2 Material resected from the scapula and peripheral tissue mass. An elastic nodular mass is observed on the anterior (outer, ventral)
surface of the scapula, 13 cm× 10 cm× 5 cm in size, with a 0.2 cm-thick pseudocapsule with a grayish yellow cut surface. The mass destructed
the medullary bone medially 6 cm in length and shows soft tissue invasion. Soft tissue distance to surgical border is 2 cm.
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tion, may occur.
Biopsy material is essential for the definitive diagnosis
of GISTs, as radiological and endoscopic examinations
are insufficient as diagnostic tools. A percutaneous bi-
opsy should not be performed in patients with poten-
tially resectable tumors, due to the low diagnostic yield
and the risk of seeding malignant cells. GISTs present in
a wide range of size (from a few millimeters to >30 cm).
They commonly arise from the wall of the GI tract.
GISTs are usually well-demarcated encapsulated firm
nodules with a tan-gray appearance on the cut surface.
Large tumors may show cystic degeneration, central ne-
crosis and hemorrhage. GISTs can be composed of spin-
dle cells, epithelioid cells, or a mixture of both spindle
and epithelioid cells (pleomorphic). The best immunos-
taining method for identifying GISTs is to test for ex-
pression of KIT, also known as CD117. About 5% of
GISTs do not stain positive for KIT. Other immunohis-
tochemical markers often observed to be positive in
GISTs are CD34 (60% to 70%) and smooth muscle actin
(30% to 40%). A small percentage of GISTs may show
positivity for desmin, or S-100. This is not important ifFigure 3 An eosinophilic tumor with lucid vacuolar cytoplasm, remin
fusiform cells was observed. The immune profile of the metastatic tumo
the diagnosis of a GIST.the GIST is c-kit-positive, several immunohistochemical
markers in the diagnosis of GISTs, the differential diag-
nosis and prognosis assessment is currently under inves-
tigation [15,16].
The liver is the most common site of GIST metastasis.
Distant metastasis to other sites, especially bone, the
lungs and lymph nodes, is relatively rare. The mandible,
spine, femur and humerus have been reported as locali-
zations of bone metastasis. Only one case of scapular
metastasis has been reported [17]. The presented report
is the second to describe scapular metastasis. Our patient
presented with a right shoulder mass. GIST metastasis
was confirmed via biopsy and our patient underwent sca-
pulectomy. The overwhelming majority of scapular
tumors are metastases from soft tissue, hepatocellular
and thyroid tumors. GIST metastases are rare. Scapula
surgery can successfully provide local control of the dis-
ease. Following such surgery, patients should continue
with medical treatment.
According to a retrospective analysis, 17 of 309 GIST
patients (5.5%) had bone metastasis; scapular metastasis
was not observed and bone metastasis was not a primary
clinical feature at their initial presentation. The patientsiscent of smooth muscle and composed of interlacing bundles of
r (c- kit and CD34 positive) and previous biopsy together confirmed
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from initial diagnosis, 252 weeks from distant recur-
rence-free status, and 135 weeks after the diagnosis of
bone metastasis. CT, MRI and PET-CT were used to
identify metastases; however, PET-CT was more effective
for diagnosis, staging, restaging and measurement of
therapeutic response of these neoplasms. Bone scanning
was not routinely performed [18].
Despite advances in drug therapy, surgical resection
remains the primary treatment of GISTs and total resec-
tion remains the most effective. However, drug treatment
should be used instead of surgery in some patients, such
as those with widespread metastasis, local progression or
a general medical condition that contraindicates surgery,
and when the surgical intervention is associated with a
high rate of morbidity and/or mortality. If technically
feasible, resection can be performed in patients with liver
metastasis; however, surgery is often not applicable due
to multiple liver metastases, very large metastases or
peritoneal involvement [19]. Hepatic artery embolization
or chemoembolization is thought to be an effective pal-
liative treatment because GISTs are often hypervascular.
Imatinib mesilate inhibits KIT tyrosine kinase activity.
Imatinib is the first molecular targeted therapy. The
current recommendation is to initiate imatinib treatment
at 400 mg daily for at least three months and then com-
mence follow-up. Initiation at 800 mg daily often causes
side effects, which eventually lead to dose reduction.
Thus, an initial dose of 400 mg daily can be increased
according to follow-up results [20,21]. In patients that
do not respond to high-dose imatinib or if resistance
develops over time, imatinib must be substituted with
sunitinib. Sunitinib malate does not cure cancer like ima-
tinib does, but it is the generally accepted second-line
treatment, as sunitinib prolongs survival in patients with
advanced GISTs [22].Conclusion
The present study is the second to describe scapular me-
tastasis of a GIST. Our patient was treated by scapulect-
omy. The overwhelming majority of scapular tumors are
metastases that arise from soft tissue, hepatocellular and
thyroid tumors. GIST metastasis occurs rarely. Scapular
surgery can successfully provide local control of the dis-
ease. Following the surgery, patients should continue
with medical treatment.Consent
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